nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—hematologic cancer	0.291	1	CiPCiCtD
Pemetrexed—Methotrexate—hematologic cancer	0.181	1	CrCtD
Pemetrexed—DCK—hematologic cancer	0.125	1	CbGaD
Pemetrexed—DCK—Nelarabine—hematologic cancer	0.0255	0.14	CbGbCtD
Pemetrexed—Pralatrexate—Methotrexate—hematologic cancer	0.0238	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—hematologic cancer	0.0238	0.2	CrCrCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—hematologic cancer	0.0238	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—hematologic cancer	0.0238	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—hematologic cancer	0.0238	0.2	CrCrCtD
Pemetrexed—DCK—Clofarabine—hematologic cancer	0.0233	0.128	CbGbCtD
Pemetrexed—SLC29A1—Fludarabine—hematologic cancer	0.019	0.105	CbGbCtD
Pemetrexed—DCK—Fludarabine—hematologic cancer	0.0176	0.0971	CbGbCtD
Pemetrexed—SLC29A1—Cytarabine—hematologic cancer	0.013	0.0715	CbGbCtD
Pemetrexed—DCK—Cytarabine—hematologic cancer	0.012	0.0662	CbGbCtD
Pemetrexed—SLC29A1—Mercaptopurine—hematologic cancer	0.0114	0.0628	CbGbCtD
Pemetrexed—DCK—Cladribine—hematologic cancer	0.0114	0.0626	CbGbCtD
Pemetrexed—ATIC—Methotrexate—hematologic cancer	0.00977	0.0538	CbGbCtD
Pemetrexed—SLC29A1—Gemcitabine—hematologic cancer	0.00791	0.0435	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—hematologic cancer	0.00776	0.0427	CbGbCtD
Pemetrexed—TYMS—Gemcitabine—hematologic cancer	0.00733	0.0403	CbGbCtD
Pemetrexed—DCK—Gemcitabine—hematologic cancer	0.00733	0.0403	CbGbCtD
Pemetrexed—DHFR—Methotrexate—hematologic cancer	0.00496	0.0273	CbGbCtD
Pemetrexed—TYMS—Methotrexate—hematologic cancer	0.00346	0.019	CbGbCtD
Pemetrexed—GART—hematopoietic system—hematologic cancer	0.000905	0.0597	CbGeAlD
Pemetrexed—SLC46A1—hematopoietic system—hematologic cancer	0.000735	0.0484	CbGeAlD
Pemetrexed—GART—gonad—hematologic cancer	0.000688	0.0454	CbGeAlD
Pemetrexed—ATIC—hematopoietic system—hematologic cancer	0.000615	0.0405	CbGeAlD
Pemetrexed—GART—blood—hematologic cancer	0.0006	0.0395	CbGeAlD
Pemetrexed—GART—bone marrow—hematologic cancer	0.00058	0.0382	CbGeAlD
Pemetrexed—GART—lung—hematologic cancer	0.000526	0.0346	CbGeAlD
Pemetrexed—Tetrahydrofolic acid—FTCD—hematologic cancer	0.000512	0.416	CrCbGaD
Pemetrexed—GART—testis—hematologic cancer	0.000496	0.0327	CbGeAlD
Pemetrexed—ATIC—gonad—hematologic cancer	0.000467	0.0308	CbGeAlD
Pemetrexed—TYMS—hematopoietic system—hematologic cancer	0.000417	0.0275	CbGeAlD
Pemetrexed—DHFR—hematopoietic system—hematologic cancer	0.000413	0.0272	CbGeAlD
Pemetrexed—ATIC—blood—hematologic cancer	0.000407	0.0268	CbGeAlD
Pemetrexed—SLC46A1—testis—hematologic cancer	0.000403	0.0265	CbGeAlD
Pemetrexed—SLC29A1—hematopoietic system—hematologic cancer	0.000374	0.0246	CbGeAlD
Pemetrexed—GART—lymph node—hematologic cancer	0.00036	0.0237	CbGeAlD
Pemetrexed—DCK—hematopoietic system—hematologic cancer	0.000357	0.0235	CbGeAlD
Pemetrexed—ATIC—lung—hematologic cancer	0.000357	0.0235	CbGeAlD
Pemetrexed—ATIC—testis—hematologic cancer	0.000337	0.0222	CbGeAlD
Pemetrexed—TYMS—gonad—hematologic cancer	0.000317	0.0209	CbGeAlD
Pemetrexed—DHFR—gonad—hematologic cancer	0.000314	0.0207	CbGeAlD
Pemetrexed—SLC46A1—lymph node—hematologic cancer	0.000292	0.0192	CbGeAlD
Pemetrexed—SLC29A1—gonad—hematologic cancer	0.000284	0.0187	CbGeAlD
Pemetrexed—TYMS—blood—hematologic cancer	0.000276	0.0182	CbGeAlD
Pemetrexed—DHFR—blood—hematologic cancer	0.000274	0.018	CbGeAlD
Pemetrexed—DCK—gonad—hematologic cancer	0.000272	0.0179	CbGeAlD
Pemetrexed—TYMS—bone marrow—hematologic cancer	0.000267	0.0176	CbGeAlD
Pemetrexed—DHFR—bone marrow—hematologic cancer	0.000265	0.0174	CbGeAlD
Pemetrexed—SLC29A1—blood—hematologic cancer	0.000248	0.0163	CbGeAlD
Pemetrexed—ATIC—lymph node—hematologic cancer	0.000244	0.0161	CbGeAlD
Pemetrexed—TYMS—lung—hematologic cancer	0.000242	0.016	CbGeAlD
Pemetrexed—DHFR—lung—hematologic cancer	0.00024	0.0158	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—hematologic cancer	0.00024	0.0158	CbGeAlD
Pemetrexed—DCK—blood—hematologic cancer	0.000237	0.0156	CbGeAlD
Pemetrexed—DCK—bone marrow—hematologic cancer	0.000229	0.0151	CbGeAlD
Pemetrexed—TYMS—testis—hematologic cancer	0.000229	0.0151	CbGeAlD
Pemetrexed—DHFR—testis—hematologic cancer	0.000226	0.0149	CbGeAlD
Pemetrexed—SLC29A1—lung—hematologic cancer	0.000217	0.0143	CbGeAlD
Pemetrexed—DCK—lung—hematologic cancer	0.000207	0.0137	CbGeAlD
Pemetrexed—SLC29A1—testis—hematologic cancer	0.000205	0.0135	CbGeAlD
Pemetrexed—DCK—testis—hematologic cancer	0.000196	0.0129	CbGeAlD
Pemetrexed—Tetrahydrofolic acid—MTR—hematologic cancer	0.000169	0.137	CrCbGaD
Pemetrexed—TYMS—lymph node—hematologic cancer	0.000166	0.0109	CbGeAlD
Pemetrexed—DHFR—lymph node—hematologic cancer	0.000164	0.0108	CbGeAlD
Pemetrexed—SLC29A1—lymph node—hematologic cancer	0.000149	0.00979	CbGeAlD
Pemetrexed—DCK—lymph node—hematologic cancer	0.000142	0.00935	CbGeAlD
Pemetrexed—Leucovorin—ABCC3—hematologic cancer	0.000141	0.115	CrCbGaD
Pemetrexed—Folic Acid—ABCC3—hematologic cancer	9.1e-05	0.0739	CrCbGaD
Pemetrexed—TYMS—Nilotinib—Imatinib—hematologic cancer	8.38e-05	0.0895	CbGdCrCtD
Pemetrexed—Methotrexate—ABCC3—hematologic cancer	6.22e-05	0.0506	CrCbGaD
Pemetrexed—DCK—Topotecan—Irinotecan—hematologic cancer	6.18e-05	0.0659	CbGdCrCtD
Pemetrexed—Tetrahydrofolic acid—MTHFR—hematologic cancer	5.77e-05	0.0469	CrCbGaD
Pemetrexed—Folic Acid—MTHFR—hematologic cancer	5.77e-05	0.0469	CrCbGaD
Pemetrexed—TYMS—Vitamin A—Alitretinoin—hematologic cancer	5.06e-05	0.054	CbGdCrCtD
Pemetrexed—Folic Acid—ABCG2—hematologic cancer	4.42e-05	0.0359	CrCbGaD
Pemetrexed—DCK—Doxorubicin—Daunorubicin—hematologic cancer	4.17e-05	0.0445	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Daunorubicin—hematologic cancer	4.17e-05	0.0445	CbGdCrCtD
Pemetrexed—Methotrexate—MTHFR—hematologic cancer	3.95e-05	0.0321	CrCbGaD
Pemetrexed—DCK—Menadione—Thalidomide—hematologic cancer	3.55e-05	0.0379	CbGdCrCtD
Pemetrexed—TYMS—Tretinoin—Alitretinoin—hematologic cancer	3.54e-05	0.0377	CbGdCrCtD
Pemetrexed—TYMS—Isotretinoin—Alitretinoin—hematologic cancer	3.54e-05	0.0377	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Teniposide—hematologic cancer	3.52e-05	0.0376	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Idarubicin—hematologic cancer	3.16e-05	0.0338	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Idarubicin—hematologic cancer	3.16e-05	0.0338	CbGdCrCtD
Pemetrexed—Methotrexate—ABCG2—hematologic cancer	3.02e-05	0.0246	CrCbGaD
Pemetrexed—TYMS—Menadione—Thalidomide—hematologic cancer	2.67e-05	0.0285	CbGdCrCtD
Pemetrexed—TYMS—Vincristine—Vinorelbine—hematologic cancer	2.24e-05	0.0239	CbGdCrCtD
Pemetrexed—TYMS—Vinorelbine—Vincristine—hematologic cancer	2.1e-05	0.0224	CbGdCrCtD
Pemetrexed—TYMS—Vinorelbine—Vinblastine—hematologic cancer	2.1e-05	0.0224	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Etoposide—hematologic cancer	2.1e-05	0.0224	CbGdCrCtD
Pemetrexed—TYMS—Vinblastine—Vinorelbine—hematologic cancer	1.8e-05	0.0193	CbGdCrCtD
Pemetrexed—TYMS—Vincristine—Vinblastine—hematologic cancer	1.79e-05	0.0191	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—hematologic cancer	1.45e-05	0.0155	CbGdCrCtD
Pemetrexed—TYMS—Vinblastine—Vincristine—hematologic cancer	1.44e-05	0.0154	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Pentostatin—hematologic cancer	1.37e-05	0.0146	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—hematologic cancer	1.34e-05	0.0143	CbGdCrCtD
Pemetrexed—Methotrexate—ALB—hematologic cancer	1.32e-05	0.0107	CrCbGaD
Pemetrexed—Methotrexate—ABCB1—hematologic cancer	1.26e-05	0.0102	CrCbGaD
Pemetrexed—TYMS—Azacitidine—Clofarabine—hematologic cancer	1.22e-05	0.013	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Nelarabine—hematologic cancer	1.15e-05	0.0122	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Fludarabine—hematologic cancer	8.95e-06	0.00955	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Gemcitabine—hematologic cancer	8.45e-06	0.00902	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Cytarabine—hematologic cancer	8.45e-06	0.00902	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Cladribine—hematologic cancer	8.24e-06	0.00879	CbGdCrCtD
Pemetrexed—DCK—Desoximetasone—Dexamethasone—hematologic cancer	6.41e-06	0.00685	CbGdCrCtD
Pemetrexed—DCK—Desoximetasone—Betamethasone—hematologic cancer	6.41e-06	0.00685	CbGdCrCtD
Pemetrexed—DCK—Desoximetasone—Triamcinolone—hematologic cancer	6.27e-06	0.00669	CbGdCrCtD
Pemetrexed—DCK—Diflorasone—Dexamethasone—hematologic cancer	6.22e-06	0.00664	CbGdCrCtD
Pemetrexed—DCK—Diflorasone—Betamethasone—hematologic cancer	6.22e-06	0.00664	CbGdCrCtD
Pemetrexed—DCK—Diflorasone—Triamcinolone—hematologic cancer	6.08e-06	0.00649	CbGdCrCtD
Pemetrexed—DCK—Desoximetasone—Prednisone—hematologic cancer	5.95e-06	0.00635	CbGdCrCtD
Pemetrexed—DCK—Desoximetasone—Prednisolone—hematologic cancer	5.81e-06	0.0062	CbGdCrCtD
Pemetrexed—DCK—Diflorasone—Prednisone—hematologic cancer	5.77e-06	0.00616	CbGdCrCtD
Pemetrexed—Pharyngitis—Epirubicin—hematologic cancer	5.7e-06	0.000104	CcSEcCtD
Pemetrexed—Fatigue—Triamcinolone—hematologic cancer	5.69e-06	0.000104	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—hematologic cancer	5.67e-06	0.000104	CcSEcCtD
Pemetrexed—Rash—Vincristine—hematologic cancer	5.66e-06	0.000103	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—hematologic cancer	5.66e-06	0.000103	CcSEcCtD
Pemetrexed—Pain—Triamcinolone—hematologic cancer	5.64e-06	0.000103	CcSEcCtD
Pemetrexed—DCK—Diflorasone—Prednisolone—hematologic cancer	5.63e-06	0.00601	CbGdCrCtD
Pemetrexed—Urethral disorder—Epirubicin—hematologic cancer	5.63e-06	0.000103	CcSEcCtD
Pemetrexed—Loss of consciousness—Prednisone—hematologic cancer	5.61e-06	0.000103	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—hematologic cancer	5.59e-06	0.000102	CcSEcCtD
Pemetrexed—Nausea—Carmustine—hematologic cancer	5.59e-06	0.000102	CcSEcCtD
Pemetrexed—Vomiting—Mitoxantrone—hematologic cancer	5.56e-06	0.000102	CcSEcCtD
Pemetrexed—Vomiting—Irinotecan—hematologic cancer	5.56e-06	0.000102	CcSEcCtD
Pemetrexed—Nausea—Alitretinoin—hematologic cancer	5.53e-06	0.000101	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—hematologic cancer	5.52e-06	0.000101	CcSEcCtD
Pemetrexed—Hypertension—Prednisone—hematologic cancer	5.51e-06	0.000101	CcSEcCtD
Pemetrexed—Rash—Irinotecan—hematologic cancer	5.51e-06	0.000101	CcSEcCtD
Pemetrexed—Rash—Mitoxantrone—hematologic cancer	5.51e-06	0.000101	CcSEcCtD
Pemetrexed—Dermatitis—Irinotecan—hematologic cancer	5.51e-06	0.000101	CcSEcCtD
Pemetrexed—Dermatitis—Mitoxantrone—hematologic cancer	5.51e-06	0.000101	CcSEcCtD
Pemetrexed—Nausea—Ifosfamide—hematologic cancer	5.47e-06	0.0001	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	5.45e-06	9.97e-05	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Betamethasone—hematologic cancer	5.45e-06	9.97e-05	CcSEcCtD
Pemetrexed—Arthralgia—Prednisone—hematologic cancer	5.44e-06	9.94e-05	CcSEcCtD
Pemetrexed—Myalgia—Prednisone—hematologic cancer	5.44e-06	9.94e-05	CcSEcCtD
Pemetrexed—Diarrhoea—Cisplatin—hematologic cancer	5.43e-06	9.93e-05	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—hematologic cancer	5.43e-06	9.92e-05	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—hematologic cancer	5.42e-06	9.9e-05	CcSEcCtD
Pemetrexed—Vomiting—Gemcitabine—hematologic cancer	5.42e-06	9.9e-05	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	5.4e-06	9.87e-05	CcSEcCtD
Pemetrexed—Rash—Gemcitabine—hematologic cancer	5.37e-06	9.81e-05	CcSEcCtD
Pemetrexed—Dermatitis—Gemcitabine—hematologic cancer	5.37e-06	9.81e-05	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—hematologic cancer	5.36e-06	9.8e-05	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—hematologic cancer	5.36e-06	9.79e-05	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—hematologic cancer	5.34e-06	9.75e-05	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—hematologic cancer	5.34e-06	9.75e-05	CcSEcCtD
Pemetrexed—Nausea—Vincristine—hematologic cancer	5.33e-06	9.75e-05	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—hematologic cancer	5.31e-06	9.7e-05	CcSEcCtD
Pemetrexed—Hypersensitivity—Prednisolone—hematologic cancer	5.29e-06	9.66e-05	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—hematologic cancer	5.27e-06	9.63e-05	CcSEcCtD
Pemetrexed—Dyspepsia—Dexamethasone—hematologic cancer	5.27e-06	9.63e-05	CcSEcCtD
Pemetrexed—Dyspepsia—Betamethasone—hematologic cancer	5.27e-06	9.63e-05	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—hematologic cancer	5.24e-06	9.58e-05	CcSEcCtD
Pemetrexed—Urticaria—Triamcinolone—hematologic cancer	5.24e-06	9.58e-05	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—hematologic cancer	5.23e-06	9.55e-05	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—hematologic cancer	5.22e-06	9.54e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Triamcinolone—hematologic cancer	5.21e-06	9.53e-05	CcSEcCtD
Pemetrexed—Anaphylactic shock—Prednisone—hematologic cancer	5.21e-06	9.53e-05	CcSEcCtD
Pemetrexed—Oedema—Prednisone—hematologic cancer	5.21e-06	9.53e-05	CcSEcCtD
Pemetrexed—TYMS—Clobetasol propionate—Betamethasone—hematologic cancer	5.21e-06	0.00556	CbGdCrCtD
Pemetrexed—TYMS—Clobetasol propionate—Dexamethasone—hematologic cancer	5.21e-06	0.00556	CbGdCrCtD
Pemetrexed—Urethral disorder—Doxorubicin—hematologic cancer	5.2e-06	9.51e-05	CcSEcCtD
Pemetrexed—Decreased appetite—Betamethasone—hematologic cancer	5.2e-06	9.51e-05	CcSEcCtD
Pemetrexed—Decreased appetite—Dexamethasone—hematologic cancer	5.2e-06	9.51e-05	CcSEcCtD
Pemetrexed—Nausea—Mitoxantrone—hematologic cancer	5.19e-06	9.49e-05	CcSEcCtD
Pemetrexed—Nausea—Irinotecan—hematologic cancer	5.19e-06	9.49e-05	CcSEcCtD
Pemetrexed—Infection—Prednisone—hematologic cancer	5.18e-06	9.46e-05	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.17e-06	9.44e-05	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.17e-06	9.44e-05	CcSEcCtD
Pemetrexed—Fatigue—Betamethasone—hematologic cancer	5.16e-06	9.43e-05	CcSEcCtD
Pemetrexed—Fatigue—Dexamethasone—hematologic cancer	5.16e-06	9.43e-05	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—hematologic cancer	5.15e-06	9.4e-05	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Dexamethasone—hematologic cancer	5.14e-06	0.00548	CbGdCrCtD
Pemetrexed—TYMS—Flunisolide—Betamethasone—hematologic cancer	5.14e-06	0.00548	CbGdCrCtD
Pemetrexed—Shock—Prednisone—hematologic cancer	5.13e-06	9.37e-05	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—hematologic cancer	5.13e-06	9.37e-05	CcSEcCtD
Pemetrexed—Pain—Betamethasone—hematologic cancer	5.12e-06	9.35e-05	CcSEcCtD
Pemetrexed—Pain—Dexamethasone—hematologic cancer	5.12e-06	9.35e-05	CcSEcCtD
Pemetrexed—Nervous system disorder—Prednisone—hematologic cancer	5.11e-06	9.34e-05	CcSEcCtD
Pemetrexed—TYMS—Clobetasol propionate—Triamcinolone—hematologic cancer	5.09e-06	0.00543	CbGdCrCtD
Pemetrexed—TYMS—Triamcinolone—Dexamethasone—hematologic cancer	5.08e-06	0.00543	CbGdCrCtD
Pemetrexed—TYMS—Triamcinolone—Betamethasone—hematologic cancer	5.08e-06	0.00543	CbGdCrCtD
Pemetrexed—Alopecia—Epirubicin—hematologic cancer	5.07e-06	9.27e-05	CcSEcCtD
Pemetrexed—Skin disorder—Prednisone—hematologic cancer	5.06e-06	9.25e-05	CcSEcCtD
Pemetrexed—Nausea—Gemcitabine—hematologic cancer	5.06e-06	9.25e-05	CcSEcCtD
Pemetrexed—Vomiting—Cisplatin—hematologic cancer	5.05e-06	9.22e-05	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—hematologic cancer	5.02e-06	9.17e-05	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Triamcinolone—hematologic cancer	5.02e-06	0.00536	CbGdCrCtD
Pemetrexed—Rash—Cisplatin—hematologic cancer	5.01e-06	9.15e-05	CcSEcCtD
Pemetrexed—Dermatitis—Cisplatin—hematologic cancer	5e-06	9.14e-05	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—hematologic cancer	5e-06	9.13e-05	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—hematologic cancer	5e-06	9.13e-05	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—hematologic cancer	4.98e-06	9.09e-05	CcSEcCtD
Pemetrexed—Anorexia—Prednisone—hematologic cancer	4.97e-06	9.08e-05	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—hematologic cancer	4.96e-06	9.07e-05	CcSEcCtD
Pemetrexed—TYMS—Fluticasone Propionate—Dexamethasone—hematologic cancer	4.96e-06	0.00529	CbGdCrCtD
Pemetrexed—TYMS—Fluticasone Propionate—Betamethasone—hematologic cancer	4.96e-06	0.00529	CbGdCrCtD
Pemetrexed—Anaemia—Methotrexate—hematologic cancer	4.93e-06	9.02e-05	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Betamethasone—hematologic cancer	4.89e-06	8.94e-05	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.89e-06	8.94e-05	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—hematologic cancer	4.89e-06	8.94e-05	CcSEcCtD
Pemetrexed—Hypersensitivity—Triamcinolone—hematologic cancer	4.86e-06	8.88e-05	CcSEcCtD
Pemetrexed—TYMS—Fluticasone Propionate—Triamcinolone—hematologic cancer	4.84e-06	0.00517	CbGdCrCtD
Pemetrexed—TYMS—Clobetasol propionate—Prednisone—hematologic cancer	4.83e-06	0.00515	CbGdCrCtD
Pemetrexed—Dizziness—Etoposide—hematologic cancer	4.81e-06	8.79e-05	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—hematologic cancer	4.78e-06	8.73e-05	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Prednisone—hematologic cancer	4.76e-06	0.00508	CbGdCrCtD
Pemetrexed—Urticaria—Dexamethasone—hematologic cancer	4.76e-06	8.69e-05	CcSEcCtD
Pemetrexed—Urticaria—Betamethasone—hematologic cancer	4.76e-06	8.69e-05	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.75e-06	8.68e-05	CcSEcCtD
Pemetrexed—Dizziness—Prednisolone—hematologic cancer	4.74e-06	8.67e-05	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—hematologic cancer	4.74e-06	8.67e-05	CcSEcCtD
Pemetrexed—Asthenia—Triamcinolone—hematologic cancer	4.73e-06	8.65e-05	CcSEcCtD
Pemetrexed—Abdominal pain—Dexamethasone—hematologic cancer	4.73e-06	8.65e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Betamethasone—hematologic cancer	4.73e-06	8.65e-05	CcSEcCtD
Pemetrexed—Abdominal pain—Betamethasone—hematologic cancer	4.73e-06	8.65e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Dexamethasone—hematologic cancer	4.73e-06	8.65e-05	CcSEcCtD
Pemetrexed—Nausea—Cisplatin—hematologic cancer	4.72e-06	8.62e-05	CcSEcCtD
Pemetrexed—TYMS—Triamcinolone—Prednisone—hematologic cancer	4.71e-06	0.00503	CbGdCrCtD
Pemetrexed—TYMS—Clobetasol propionate—Prednisolone—hematologic cancer	4.71e-06	0.00503	CbGdCrCtD
Pemetrexed—Alopecia—Doxorubicin—hematologic cancer	4.69e-06	8.57e-05	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Dexamethasone—hematologic cancer	4.69e-06	0.005	CbGdCrCtD
Pemetrexed—TYMS—Diflorasone—Betamethasone—hematologic cancer	4.69e-06	0.005	CbGdCrCtD
Pemetrexed—Pruritus—Triamcinolone—hematologic cancer	4.67e-06	8.53e-05	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Prednisolone—hematologic cancer	4.65e-06	0.00496	CbGdCrCtD
Pemetrexed—Vomiting—Etoposide—hematologic cancer	4.62e-06	8.45e-05	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—hematologic cancer	4.62e-06	8.45e-05	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—hematologic cancer	4.62e-06	8.45e-05	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—hematologic cancer	4.62e-06	8.44e-05	CcSEcCtD
Pemetrexed—TYMS—Triamcinolone—Prednisolone—hematologic cancer	4.6e-06	0.00491	CbGdCrCtD
Pemetrexed—Dyspepsia—Prednisone—hematologic cancer	4.59e-06	8.39e-05	CcSEcCtD
Pemetrexed—Rash—Etoposide—hematologic cancer	4.59e-06	8.38e-05	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—hematologic cancer	4.58e-06	8.37e-05	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Triamcinolone—hematologic cancer	4.58e-06	0.00489	CbGdCrCtD
Pemetrexed—Chest pain—Methotrexate—hematologic cancer	4.54e-06	8.3e-05	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—hematologic cancer	4.54e-06	8.3e-05	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—hematologic cancer	4.54e-06	8.3e-05	CcSEcCtD
Pemetrexed—Decreased appetite—Prednisone—hematologic cancer	4.53e-06	8.28e-05	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—hematologic cancer	4.53e-06	8.27e-05	CcSEcCtD
Pemetrexed—Rash—Prednisolone—hematologic cancer	4.52e-06	8.27e-05	CcSEcCtD
Pemetrexed—Dermatitis—Prednisolone—hematologic cancer	4.52e-06	8.26e-05	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.51e-06	8.25e-05	CcSEcCtD
Pemetrexed—Fatigue—Prednisone—hematologic cancer	4.49e-06	8.21e-05	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—hematologic cancer	4.48e-06	8.19e-05	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—hematologic cancer	4.47e-06	8.17e-05	CcSEcCtD
Pemetrexed—Constipation—Prednisone—hematologic cancer	4.46e-06	8.15e-05	CcSEcCtD
Pemetrexed—Loss of consciousness—Epirubicin—hematologic cancer	4.39e-06	8.02e-05	CcSEcCtD
Pemetrexed—Dizziness—Triamcinolone—hematologic cancer	4.36e-06	7.97e-05	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—hematologic cancer	4.36e-06	7.96e-05	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Prednisone—hematologic cancer	4.35e-06	0.00464	CbGdCrCtD
Pemetrexed—Infection—Methotrexate—hematologic cancer	4.33e-06	7.91e-05	CcSEcCtD
Pemetrexed—Nausea—Etoposide—hematologic cancer	4.32e-06	7.89e-05	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—hematologic cancer	4.31e-06	7.88e-05	CcSEcCtD
Pemetrexed—Asthenia—Betamethasone—hematologic cancer	4.29e-06	7.85e-05	CcSEcCtD
Pemetrexed—Asthenia—Dexamethasone—hematologic cancer	4.29e-06	7.85e-05	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—hematologic cancer	4.27e-06	7.81e-05	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—hematologic cancer	4.27e-06	7.81e-05	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—hematologic cancer	4.27e-06	7.79e-05	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Prednisone—hematologic cancer	4.26e-06	7.79e-05	CcSEcCtD
Pemetrexed—Nausea—Prednisolone—hematologic cancer	4.26e-06	7.79e-05	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—hematologic cancer	4.25e-06	7.77e-05	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—hematologic cancer	4.25e-06	7.77e-05	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—hematologic cancer	4.25e-06	7.77e-05	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Prednisolone—hematologic cancer	4.24e-06	0.00453	CbGdCrCtD
Pemetrexed—Pruritus—Dexamethasone—hematologic cancer	4.23e-06	7.74e-05	CcSEcCtD
Pemetrexed—Pruritus—Betamethasone—hematologic cancer	4.23e-06	7.74e-05	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—hematologic cancer	4.23e-06	7.73e-05	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.22e-06	7.72e-05	CcSEcCtD
Pemetrexed—Vomiting—Triamcinolone—hematologic cancer	4.19e-06	7.67e-05	CcSEcCtD
Pemetrexed—Rash—Triamcinolone—hematologic cancer	4.16e-06	7.6e-05	CcSEcCtD
Pemetrexed—Dermatitis—Triamcinolone—hematologic cancer	4.16e-06	7.59e-05	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—hematologic cancer	4.15e-06	7.59e-05	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—hematologic cancer	4.15e-06	7.57e-05	CcSEcCtD
Pemetrexed—Urticaria—Prednisone—hematologic cancer	4.14e-06	7.57e-05	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—hematologic cancer	4.14e-06	7.56e-05	CcSEcCtD
Pemetrexed—Abdominal pain—Prednisone—hematologic cancer	4.12e-06	7.53e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Prednisone—hematologic cancer	4.12e-06	7.53e-05	CcSEcCtD
Pemetrexed—TYMS—Budesonide—Betamethasone—hematologic cancer	4.11e-06	0.00439	CbGdCrCtD
Pemetrexed—TYMS—Budesonide—Dexamethasone—hematologic cancer	4.11e-06	0.00439	CbGdCrCtD
Pemetrexed—Diarrhoea—Dexamethasone—hematologic cancer	4.1e-06	7.48e-05	CcSEcCtD
Pemetrexed—Diarrhoea—Betamethasone—hematologic cancer	4.1e-06	7.48e-05	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—hematologic cancer	4.08e-06	7.45e-05	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—hematologic cancer	4.08e-06	7.45e-05	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—hematologic cancer	4.06e-06	7.42e-05	CcSEcCtD
Pemetrexed—Infection—Epirubicin—hematologic cancer	4.05e-06	7.4e-05	CcSEcCtD
Pemetrexed—TYMS—Budesonide—Triamcinolone—hematologic cancer	4.01e-06	0.00428	CbGdCrCtD
Pemetrexed—Shock—Epirubicin—hematologic cancer	4.01e-06	7.33e-05	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—hematologic cancer	4e-06	7.31e-05	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—hematologic cancer	3.99e-06	7.29e-05	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—hematologic cancer	3.99e-06	7.29e-05	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.97e-06	7.25e-05	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—hematologic cancer	3.96e-06	7.24e-05	CcSEcCtD
Pemetrexed—Dizziness—Dexamethasone—hematologic cancer	3.96e-06	7.23e-05	CcSEcCtD
Pemetrexed—Dizziness—Betamethasone—hematologic cancer	3.96e-06	7.23e-05	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—hematologic cancer	3.94e-06	7.19e-05	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—hematologic cancer	3.94e-06	7.19e-05	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—hematologic cancer	3.94e-06	7.19e-05	CcSEcCtD
Pemetrexed—Nausea—Triamcinolone—hematologic cancer	3.92e-06	7.16e-05	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.91e-06	7.14e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PIK3CG—hematologic cancer	3.91e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Disease—LCK—hematologic cancer	3.9e-06	0.000128	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	3.89e-06	0.000128	CbGpPWpGaD
Pemetrexed—Anorexia—Epirubicin—hematologic cancer	3.89e-06	7.1e-05	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—hematologic cancer	3.88e-06	7.1e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—ABCC3—hematologic cancer	3.88e-06	0.000128	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TXN—hematologic cancer	3.88e-06	0.000128	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTO1—hematologic cancer	3.88e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NUP98—hematologic cancer	3.84e-06	0.000126	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Prednisone—hematologic cancer	3.84e-06	7.02e-05	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—hematologic cancer	3.83e-06	7.01e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—H3F3A—hematologic cancer	3.82e-06	0.000126	CbGpPWpGaD
Pemetrexed—TYMS—Budesonide—Prednisone—hematologic cancer	3.81e-06	0.00407	CbGdCrCtD
Pemetrexed—Vomiting—Betamethasone—hematologic cancer	3.81e-06	6.95e-05	CcSEcCtD
Pemetrexed—Vomiting—Dexamethasone—hematologic cancer	3.81e-06	6.95e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—SPHK1—hematologic cancer	3.8e-06	0.000125	CbGpPWpGaD
Pemetrexed—Decreased appetite—Methotrexate—hematologic cancer	3.79e-06	6.92e-05	CcSEcCtD
Pemetrexed—Rash—Dexamethasone—hematologic cancer	3.77e-06	6.9e-05	CcSEcCtD
Pemetrexed—Rash—Betamethasone—hematologic cancer	3.77e-06	6.9e-05	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—hematologic cancer	3.77e-06	6.89e-05	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—hematologic cancer	3.77e-06	6.89e-05	CcSEcCtD
Pemetrexed—Dermatitis—Dexamethasone—hematologic cancer	3.77e-06	6.89e-05	CcSEcCtD
Pemetrexed—Dermatitis—Betamethasone—hematologic cancer	3.77e-06	6.89e-05	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.76e-06	6.87e-05	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—hematologic cancer	3.76e-06	6.86e-05	CcSEcCtD
Pemetrexed—SLC46A1—Disease—BAD—hematologic cancer	3.75e-06	0.000123	CbGpPWpGaD
Pemetrexed—Infection—Doxorubicin—hematologic cancer	3.75e-06	6.85e-05	CcSEcCtD
Pemetrexed—Asthenia—Prednisone—hematologic cancer	3.74e-06	6.83e-05	CcSEcCtD
Pemetrexed—GART—Metabolism—PTEN—hematologic cancer	3.73e-06	0.000123	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ADCY7—hematologic cancer	3.73e-06	0.000122	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NCOA3—hematologic cancer	3.73e-06	0.000122	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK2—hematologic cancer	3.73e-06	0.000122	CbGpPWpGaD
Pemetrexed—Pain—Methotrexate—hematologic cancer	3.73e-06	6.81e-05	CcSEcCtD
Pemetrexed—TYMS—Budesonide—Prednisolone—hematologic cancer	3.72e-06	0.00397	CbGdCrCtD
Pemetrexed—SLC46A1—Disease—NOTCH1—hematologic cancer	3.72e-06	0.000122	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PRKCZ—hematologic cancer	3.72e-06	0.000122	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.71e-06	6.79e-05	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—hematologic cancer	3.71e-06	6.78e-05	CcSEcCtD
Pemetrexed—DHFR—Metabolism—NUP214—hematologic cancer	3.7e-06	0.000122	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Doxorubicin—hematologic cancer	3.7e-06	6.76e-05	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—hematologic cancer	3.69e-06	6.75e-05	CcSEcCtD
Pemetrexed—Pruritus—Prednisone—hematologic cancer	3.69e-06	6.74e-05	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—hematologic cancer	3.66e-06	6.7e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—CALR—hematologic cancer	3.65e-06	0.00012	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—UGT1A1—hematologic cancer	3.65e-06	0.00012	CbGpPWpGaD
Pemetrexed—TYMS—Danazol—Prednisone—hematologic cancer	3.65e-06	0.0039	CbGdCrCtD
Pemetrexed—SLC46A1—Disease—CD80—hematologic cancer	3.64e-06	0.00012	CbGpPWpGaD
Pemetrexed—Dyspnoea—Epirubicin—hematologic cancer	3.63e-06	6.64e-05	CcSEcCtD
Pemetrexed—SLC46A1—Disease—KIT—hematologic cancer	3.63e-06	0.000119	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCG2—hematologic cancer	3.63e-06	0.000119	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—MTR—hematologic cancer	3.63e-06	0.000119	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—MTHFR—hematologic cancer	3.62e-06	0.000119	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CREBBP—hematologic cancer	3.62e-06	0.000119	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—hematologic cancer	3.6e-06	6.57e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—PARP1—hematologic cancer	3.59e-06	0.000118	CbGpPWpGaD
Pemetrexed—Dyspepsia—Epirubicin—hematologic cancer	3.59e-06	6.56e-05	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	3.58e-06	0.000117	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTPN11—hematologic cancer	3.57e-06	0.000117	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CD44—hematologic cancer	3.57e-06	0.000117	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NQO1—hematologic cancer	3.57e-06	0.000117	CbGpPWpGaD
Pemetrexed—Diarrhoea—Prednisone—hematologic cancer	3.57e-06	6.52e-05	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—hematologic cancer	3.56e-06	6.51e-05	CcSEcCtD
Pemetrexed—GART—Metabolism—EP300—hematologic cancer	3.56e-06	0.000117	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ENO2—hematologic cancer	3.56e-06	0.000117	CbGpPWpGaD
Pemetrexed—Nausea—Betamethasone—hematologic cancer	3.56e-06	6.5e-05	CcSEcCtD
Pemetrexed—Nausea—Dexamethasone—hematologic cancer	3.56e-06	6.5e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—SLC22A1—hematologic cancer	3.55e-06	0.000117	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CRABP1—hematologic cancer	3.55e-06	0.000117	CbGpPWpGaD
Pemetrexed—Decreased appetite—Epirubicin—hematologic cancer	3.54e-06	6.48e-05	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—ATM—hematologic cancer	3.54e-06	0.000116	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FBXW7—hematologic cancer	3.53e-06	0.000116	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK4—hematologic cancer	3.52e-06	0.000116	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.52e-06	6.43e-05	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—hematologic cancer	3.51e-06	6.42e-05	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—RB1—hematologic cancer	3.51e-06	0.000115	CbGpPWpGaD
Pemetrexed—Constipation—Epirubicin—hematologic cancer	3.49e-06	6.37e-05	CcSEcCtD
Pemetrexed—Pain—Epirubicin—hematologic cancer	3.49e-06	6.37e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—HDAC2—hematologic cancer	3.46e-06	0.000114	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CXCR4—hematologic cancer	3.46e-06	0.000114	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALOX5—hematologic cancer	3.46e-06	0.000114	CbGpPWpGaD
Pemetrexed—Urticaria—Methotrexate—hematologic cancer	3.46e-06	6.32e-05	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	3.46e-06	0.000114	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREB1—hematologic cancer	3.46e-06	0.000114	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTT1—hematologic cancer	3.45e-06	0.000113	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—hematologic cancer	3.45e-06	0.000113	CbGpPWpGaD
Pemetrexed—Dizziness—Prednisone—hematologic cancer	3.45e-06	6.3e-05	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—hematologic cancer	3.44e-06	6.29e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—hematologic cancer	3.44e-06	6.29e-05	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.44e-06	6.28e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PIK3CD—hematologic cancer	3.43e-06	0.000113	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—hematologic cancer	3.42e-06	0.000112	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD44—hematologic cancer	3.42e-06	0.000112	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—hematologic cancer	3.42e-06	0.000112	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ALB—hematologic cancer	3.39e-06	0.000111	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYCS—hematologic cancer	3.38e-06	0.000111	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CBL—hematologic cancer	3.37e-06	0.000111	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IL6R—hematologic cancer	3.37e-06	0.000111	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SDC1—hematologic cancer	3.37e-06	0.000111	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREBBP—hematologic cancer	3.37e-06	0.000111	CbGpPWpGaD
Pemetrexed—Dyspnoea—Doxorubicin—hematologic cancer	3.36e-06	6.15e-05	CcSEcCtD
Pemetrexed—DCK—Metabolism—HSP90AA1—hematologic cancer	3.36e-06	0.00011	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NUP98—hematologic cancer	3.35e-06	0.00011	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Epirubicin—hematologic cancer	3.33e-06	6.09e-05	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—hematologic cancer	3.32e-06	0.000109	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—hematologic cancer	3.32e-06	6.07e-05	CcSEcCtD
Pemetrexed—Vomiting—Prednisone—hematologic cancer	3.31e-06	6.06e-05	CcSEcCtD
Pemetrexed—Rash—Prednisone—hematologic cancer	3.29e-06	6.01e-05	CcSEcCtD
Pemetrexed—Dermatitis—Prednisone—hematologic cancer	3.28e-06	6e-05	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—hematologic cancer	3.28e-06	5.99e-05	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.26e-06	5.95e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—ADCY7—hematologic cancer	3.25e-06	0.000107	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOA3—hematologic cancer	3.25e-06	0.000107	CbGpPWpGaD
Pemetrexed—Fatigue—Doxorubicin—hematologic cancer	3.25e-06	5.94e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PIK3R1—hematologic cancer	3.24e-06	0.000106	CbGpPWpGaD
Pemetrexed—Urticaria—Epirubicin—hematologic cancer	3.24e-06	5.92e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—NUP214—hematologic cancer	3.23e-06	0.000106	CbGpPWpGaD
Pemetrexed—Constipation—Doxorubicin—hematologic cancer	3.23e-06	5.9e-05	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—hematologic cancer	3.23e-06	5.9e-05	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—hematologic cancer	3.22e-06	5.89e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—hematologic cancer	3.22e-06	5.89e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—HSP90AA1—hematologic cancer	3.22e-06	0.000106	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAP2K1—hematologic cancer	3.22e-06	0.000106	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Methotrexate—hematologic cancer	3.21e-06	5.87e-05	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PIK3CD—hematologic cancer	3.2e-06	0.000105	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCG2—hematologic cancer	3.17e-06	0.000104	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MTR—hematologic cancer	3.17e-06	0.000104	CbGpPWpGaD
Pemetrexed—Asthenia—Methotrexate—hematologic cancer	3.13e-06	5.71e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—STAT1—hematologic cancer	3.1e-06	0.000102	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ENO2—hematologic cancer	3.1e-06	0.000102	CbGpPWpGaD
Pemetrexed—Nausea—Prednisone—hematologic cancer	3.1e-06	5.66e-05	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.08e-06	5.64e-05	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—hematologic cancer	3.08e-06	0.000101	CbGpPWpGaD
Pemetrexed—Pruritus—Methotrexate—hematologic cancer	3.08e-06	5.63e-05	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—RB1—hematologic cancer	3.06e-06	0.000101	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FGF2—hematologic cancer	3.06e-06	0.0001	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—hematologic cancer	3.06e-06	0.0001	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CG—hematologic cancer	3.04e-06	9.99e-05	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—IL6—hematologic cancer	3.04e-06	9.98e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3R1—hematologic cancer	3.02e-06	9.91e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTT1—hematologic cancer	3.01e-06	9.89e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—hematologic cancer	3.01e-06	9.88e-05	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—hematologic cancer	3e-06	5.49e-05	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—hematologic cancer	3e-06	5.48e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PIK3CB—hematologic cancer	2.99e-06	9.83e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MDM2—hematologic cancer	2.99e-06	9.82e-05	CbGpPWpGaD
Pemetrexed—Abdominal pain—Doxorubicin—hematologic cancer	2.98e-06	5.45e-05	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—hematologic cancer	2.98e-06	5.45e-05	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—hematologic cancer	2.98e-06	5.45e-05	CcSEcCtD
Pemetrexed—DCK—Metabolism—GSTP1—hematologic cancer	2.98e-06	9.77e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SDC1—hematologic cancer	2.94e-06	9.66e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—JAK2—hematologic cancer	2.93e-06	9.63e-05	CbGpPWpGaD
Pemetrexed—Asthenia—Epirubicin—hematologic cancer	2.93e-06	5.35e-05	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	2.92e-06	9.59e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—hematologic cancer	2.91e-06	9.57e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GRB2—hematologic cancer	2.9e-06	9.54e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFA—hematologic cancer	2.9e-06	9.51e-05	CbGpPWpGaD
Pemetrexed—Pruritus—Epirubicin—hematologic cancer	2.88e-06	5.27e-05	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—hematologic cancer	2.88e-06	5.26e-05	CcSEcCtD
Pemetrexed—DHFR—Metabolism—NQO1—hematologic cancer	2.87e-06	9.42e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CD44—hematologic cancer	2.87e-06	9.42e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MDM2—hematologic cancer	2.86e-06	9.4e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KITLG—hematologic cancer	2.86e-06	9.38e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CREBBP—hematologic cancer	2.82e-06	9.27e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—hematologic cancer	2.82e-06	9.26e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ABCB1—hematologic cancer	2.82e-06	9.25e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT5A—hematologic cancer	2.79e-06	9.17e-05	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—hematologic cancer	2.79e-06	5.1e-05	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PIK3CB—hematologic cancer	2.79e-06	9.14e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MTOR—hematologic cancer	2.79e-06	9.14e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CD4—hematologic cancer	2.78e-06	9.13e-05	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Doxorubicin—hematologic cancer	2.78e-06	5.08e-05	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—hematologic cancer	2.77e-06	5.06e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—CDKN2B—hematologic cancer	2.77e-06	9.09e-05	CbGpPWpGaD
Pemetrexed—Rash—Methotrexate—hematologic cancer	2.75e-06	5.02e-05	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—hematologic cancer	2.74e-06	5.02e-05	CcSEcCtD
Pemetrexed—DCK—Metabolism—NCOR1—hematologic cancer	2.74e-06	8.98e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTM1—hematologic cancer	2.74e-06	8.98e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—hematologic cancer	2.73e-06	8.97e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYCS—hematologic cancer	2.71e-06	8.91e-05	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—hematologic cancer	2.71e-06	4.95e-05	CcSEcCtD
Pemetrexed—DHFR—Metabolism—HSP90AA1—hematologic cancer	2.7e-06	8.85e-05	CbGpPWpGaD
Pemetrexed—Dizziness—Epirubicin—hematologic cancer	2.7e-06	4.93e-05	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—hematologic cancer	2.69e-06	8.84e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—hematologic cancer	2.68e-06	8.81e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD86—hematologic cancer	2.68e-06	8.79e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CD—hematologic cancer	2.68e-06	8.79e-05	CbGpPWpGaD
Pemetrexed—Pruritus—Doxorubicin—hematologic cancer	2.67e-06	4.88e-05	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—hematologic cancer	2.67e-06	8.75e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ALB—hematologic cancer	2.64e-06	8.67e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HES1—hematologic cancer	2.64e-06	8.67e-05	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—hematologic cancer	2.63e-06	8.65e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NCOR1—hematologic cancer	2.62e-06	8.62e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—hematologic cancer	2.61e-06	8.58e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MDM2—hematologic cancer	2.61e-06	8.57e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—hematologic cancer	2.61e-06	8.56e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGF1—hematologic cancer	2.6e-06	8.52e-05	CbGpPWpGaD
Pemetrexed—Vomiting—Epirubicin—hematologic cancer	2.59e-06	4.74e-05	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—hematologic cancer	2.59e-06	4.73e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PTEN—hematologic cancer	2.59e-06	8.49e-05	CbGpPWpGaD
Pemetrexed—Diarrhoea—Doxorubicin—hematologic cancer	2.58e-06	4.72e-05	CcSEcCtD
Pemetrexed—Rash—Epirubicin—hematologic cancer	2.57e-06	4.7e-05	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—hematologic cancer	2.57e-06	4.69e-05	CcSEcCtD
Pemetrexed—DHFR—Disease—FOXO1—hematologic cancer	2.56e-06	8.4e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFRB—hematologic cancer	2.55e-06	8.38e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—hematologic cancer	2.54e-06	8.35e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3R1—hematologic cancer	2.53e-06	8.3e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—hematologic cancer	2.52e-06	8.28e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFRA—hematologic cancer	2.51e-06	8.25e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—JAK1—hematologic cancer	2.5e-06	8.22e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PRKCG—hematologic cancer	2.5e-06	8.22e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NQO1—hematologic cancer	2.5e-06	8.22e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CD44—hematologic cancer	2.5e-06	8.22e-05	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—hematologic cancer	2.49e-06	4.56e-05	CcSEcCtD
Pemetrexed—ATIC—Metabolism—EP300—hematologic cancer	2.47e-06	8.1e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—hematologic cancer	2.46e-06	8.08e-05	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—hematologic cancer	2.42e-06	4.43e-05	CcSEcCtD
Pemetrexed—DCK—Metabolism—MTHFR—hematologic cancer	2.42e-06	7.94e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—hematologic cancer	2.41e-06	7.92e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—hematologic cancer	2.41e-06	7.9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MAPK3—hematologic cancer	2.4e-06	7.89e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—hematologic cancer	2.4e-06	7.88e-05	CbGpPWpGaD
Pemetrexed—Vomiting—Doxorubicin—hematologic cancer	2.4e-06	4.38e-05	CcSEcCtD
Pemetrexed—DHFR—Metabolism—GSTP1—hematologic cancer	2.39e-06	7.85e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—hematologic cancer	2.38e-06	7.83e-05	CbGpPWpGaD
Pemetrexed—Rash—Doxorubicin—hematologic cancer	2.38e-06	4.35e-05	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—hematologic cancer	2.38e-06	4.34e-05	CcSEcCtD
Pemetrexed—TYMS—Metabolism—CYCS—hematologic cancer	2.37e-06	7.77e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HSP90AA1—hematologic cancer	2.35e-06	7.72e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—hematologic cancer	2.34e-06	7.69e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—hematologic cancer	2.34e-06	7.68e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CB—hematologic cancer	2.33e-06	7.66e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTHFR—hematologic cancer	2.32e-06	7.62e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—hematologic cancer	2.31e-06	7.59e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HLA-A—hematologic cancer	2.31e-06	7.59e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—hematologic cancer	2.3e-06	7.54e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—hematologic cancer	2.27e-06	7.47e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCB1—hematologic cancer	2.26e-06	7.43e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFB—hematologic cancer	2.26e-06	7.41e-05	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—hematologic cancer	2.24e-06	4.09e-05	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SRC—hematologic cancer	2.23e-06	7.33e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TSC2—hematologic cancer	2.21e-06	7.25e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—hematologic cancer	2.2e-06	7.22e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NCOR1—hematologic cancer	2.2e-06	7.22e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTM1—hematologic cancer	2.2e-06	7.22e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—STAT3—hematologic cancer	2.15e-06	7.07e-05	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—hematologic cancer	2.15e-06	7.06e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MAPK3—hematologic cancer	2.15e-06	7.06e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—hematologic cancer	2.15e-06	7.05e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGFR3—hematologic cancer	2.12e-06	6.97e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MAPK3—hematologic cancer	2.1e-06	6.89e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—hematologic cancer	2.09e-06	6.87e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—hematologic cancer	2.09e-06	6.86e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—hematologic cancer	2.09e-06	6.85e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAPK3—hematologic cancer	2.06e-06	6.75e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—hematologic cancer	2.04e-06	6.7e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CG—hematologic cancer	2.03e-06	6.67e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—hematologic cancer	2.02e-06	6.62e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BAD—hematologic cancer	2.01e-06	6.61e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—hematologic cancer	2e-06	6.57e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—hematologic cancer	2e-06	6.55e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOTCH1—hematologic cancer	1.99e-06	6.54e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCB1—hematologic cancer	1.98e-06	6.49e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD80—hematologic cancer	1.95e-06	6.41e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KIT—hematologic cancer	1.95e-06	6.4e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—MTHFR—hematologic cancer	1.94e-06	6.38e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—hematologic cancer	1.92e-06	6.31e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTM1—hematologic cancer	1.92e-06	6.3e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOR1—hematologic cancer	1.92e-06	6.3e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTPN11—hematologic cancer	1.91e-06	6.29e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CREBBP—hematologic cancer	1.88e-06	6.18e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MAPK3—hematologic cancer	1.88e-06	6.16e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREB1—hematologic cancer	1.86e-06	6.09e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—hematologic cancer	1.85e-06	6.07e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—hematologic cancer	1.83e-06	6.01e-05	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—hematologic cancer	1.83e-06	5.99e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—hematologic cancer	1.82e-06	5.99e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IL6R—hematologic cancer	1.81e-06	5.94e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREBBP—hematologic cancer	1.81e-06	5.93e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CD—hematologic cancer	1.79e-06	5.86e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALB—hematologic cancer	1.76e-06	5.79e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAP2K1—hematologic cancer	1.72e-06	5.66e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—hematologic cancer	1.72e-06	5.64e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CD—hematologic cancer	1.71e-06	5.63e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—hematologic cancer	1.7e-06	5.57e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MTHFR—hematologic cancer	1.7e-06	5.57e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3R1—hematologic cancer	1.69e-06	5.54e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGF2—hematologic cancer	1.64e-06	5.39e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CG—hematologic cancer	1.63e-06	5.36e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3R1—hematologic cancer	1.62e-06	5.31e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—JAK2—hematologic cancer	1.57e-06	5.16e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—hematologic cancer	1.57e-06	5.16e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CB—hematologic cancer	1.56e-06	5.11e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MDM2—hematologic cancer	1.53e-06	5.04e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CREBBP—hematologic cancer	1.51e-06	4.97e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IL6—hematologic cancer	1.5e-06	4.94e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—hematologic cancer	1.5e-06	4.92e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTOR—hematologic cancer	1.49e-06	4.9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CB—hematologic cancer	1.49e-06	4.9e-05	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—hematologic cancer	1.49e-06	4.9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD4—hematologic cancer	1.49e-06	4.89e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CD—hematologic cancer	1.43e-06	4.71e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CG—hematologic cancer	1.42e-06	4.68e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—hematologic cancer	1.42e-06	4.67e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALB—hematologic cancer	1.42e-06	4.65e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1B—hematologic cancer	1.4e-06	4.6e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—hematologic cancer	1.39e-06	4.55e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3R1—hematologic cancer	1.35e-06	4.45e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—hematologic cancer	1.34e-06	4.42e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CREBBP—hematologic cancer	1.32e-06	4.34e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—hematologic cancer	1.29e-06	4.25e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—hematologic cancer	1.29e-06	4.24e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—hematologic cancer	1.28e-06	4.21e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CD—hematologic cancer	1.25e-06	4.11e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CB—hematologic cancer	1.25e-06	4.11e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALB—hematologic cancer	1.24e-06	4.06e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—hematologic cancer	1.23e-06	4.04e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—hematologic cancer	1.2e-06	3.93e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3R1—hematologic cancer	1.18e-06	3.88e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—hematologic cancer	1.16e-06	3.81e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT3—hematologic cancer	1.15e-06	3.79e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—hematologic cancer	1.15e-06	3.78e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAPK3—hematologic cancer	1.1e-06	3.62e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CB—hematologic cancer	1.09e-06	3.58e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—hematologic cancer	1.08e-06	3.55e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—hematologic cancer	1.07e-06	3.52e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—hematologic cancer	1.07e-06	3.51e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—hematologic cancer	1.03e-06	3.38e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—hematologic cancer	9.91e-07	3.25e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—hematologic cancer	9.49e-07	3.11e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—hematologic cancer	9.43e-07	3.1e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—hematologic cancer	9.1e-07	2.99e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—hematologic cancer	8.99e-07	2.95e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—hematologic cancer	8.42e-07	2.77e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IL6—hematologic cancer	8.06e-07	2.65e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—hematologic cancer	7.75e-07	2.54e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—hematologic cancer	7.62e-07	2.5e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—hematologic cancer	7.44e-07	2.44e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—hematologic cancer	6.65e-07	2.18e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—hematologic cancer	6.23e-07	2.04e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—hematologic cancer	5.43e-07	1.78e-05	CbGpPWpGaD
